GDR Genedrive Plc

TIDMGDR

RNS Number : 5633L

Genedrive PLC

09 September 2019

genedrive plc

("genedrive" or the "Company")

Notice of Results

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its preliminary results for the year ended 30 June 2019 on Thursday, 3 October 2019.

For further details please contact:

 
 genedrive plc                                                               www.genedriveplc.com 
 David Budd: CEO / Matthew Fowler: CFO                                        +44 (0)161 989 0245 
 
 Peel Hunt LLP                                                                +44 (0)20 7418 8900 
 James Steel / Oliver Jackson 
 
            Stanford Capital Partners Limited                                 +44 (0)20 3815 8880 
            Patrick Claridge / John Howes 
 
 Walbrook PR Ltd (Media Relations                 +44 (0)20 7933 8780 or genedrive@walbrookpr.com 
  & Investor Relations) 
                                                                +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                               741 001 
 
 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) HCV-ID kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive(R) platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive(R) HCV-ID Kit and Genedrive(R) platform in India. The Company has assays on market for the detection of certain biological targets and has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

Further details can be found at: www.genedriveplc.com and www.genedrive.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORLFMATMBMMBBL

(END) Dow Jones Newswires

September 09, 2019 02:01 ET (06:01 GMT)

Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024

Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024